Alexion Pharmaceuticals’ (ALXN) Buy Rating Reiterated at Leerink Swann

Alexion Pharmaceuticals (NASDAQ:ALXN)‘s stock had its “buy” rating reaffirmed by research analysts at Leerink Swann in a note issued to investors on Wednesday. They currently have a $169.00 target price on the biopharmaceutical company’s stock. Leerink Swann’s price objective suggests a potential upside of 54.45% from the company’s previous close.

ALXN has been the topic of several other reports. TheStreet downgraded shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price objective on the stock in a research report on Tuesday, October 31st. Royal Bank Of Canada started coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $161.00 price objective on the stock. Stifel Nicolaus cut their price objective on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research report on Tuesday, October 24th. Finally, J P Morgan Chase & Co upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $163.00 to $175.00 in a research report on Tuesday, September 5th. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $154.49.

Shares of Alexion Pharmaceuticals (NASDAQ ALXN) traded up $0.52 during trading hours on Wednesday, reaching $109.42. 1,935,700 shares of the company traded hands, compared to its average volume of 2,286,650. The company has a market cap of $24,329.31, a P/E ratio of 22.27, a PEG ratio of 1.18 and a beta of 1.18. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.12. The firm had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. Alexion Pharmaceuticals’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period last year, the firm posted $1.23 EPS. sell-side analysts anticipate that Alexion Pharmaceuticals will post 4.82 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the business. Commerzbank Aktiengesellschaft FI raised its holdings in shares of Alexion Pharmaceuticals by 151.5% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 132,698 shares of the biopharmaceutical company’s stock worth $16,145,000 after purchasing an additional 79,943 shares in the last quarter. HPM Partners LLC raised its holdings in shares of Alexion Pharmaceuticals by 267.2% in the 2nd quarter. HPM Partners LLC now owns 6,680 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 4,861 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Alexion Pharmaceuticals by 720.0% in the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock worth $748,116,000 after purchasing an additional 4,682,336 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Alexion Pharmaceuticals by 4,509.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock worth $124,037,000 after purchasing an additional 864,967 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of Alexion Pharmaceuticals by 1.2% in the 2nd quarter. Principal Financial Group Inc. now owns 335,525 shares of the biopharmaceutical company’s stock worth $40,823,000 after purchasing an additional 4,115 shares in the last quarter. Institutional investors own 94.16% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/12/07/alexion-pharmaceuticals-alxn-buy-rating-reiterated-at-leerink-swann.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply